▮ DFV TERMINAL
--:--:-- UTC SIGN IN
F1 Terminal / BCTXZ

BCTXZ — BriaCell Therapeutics Corp.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1610820 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Apr 2026 0 — -7,620,794 -7,164,507 27,071,310 6,880,221 3,662,350
Jan 2026 0 — -7,531,266 -7,221,820 33,594,454 29,903,628 3,380,646
Oct 2025 0 — -8,322,943 -8,197,565 13,075,050 2,714,012 3,724,646
Apr 2025 0 — -6,328,255 -6,126,902 17,001,798 12,460,253 5,060,645

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-29,855,229
Investing CF
$-8,900,576
Financing CF
$42,588,817
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-06-14

Balance + Analyst (yfinance extras)

Retained Earnings
$-134,339,456
Inventory
—
Receivables
$2,588,749
ST Investments
$15,924,204
EBIT TTM
$-29,249,583
Pretax Income TTM
$-29,037,205
Interest Exp TTM
$66,610
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Jul 2024 0 -33,330,076 -4,791,466 5,872,261 8,557,193 — -24,126,128
Jul 2023 0 -23,272,264 -20,302,394 27,163,577 30,940,758 — -23,744,860
Jul 2022 0 -15,285,553 -26,838,903 42,577,041 32,248,109 — -12,484,376
Jul 2021 0 -6,972,344 -13,816,200 58,043,762 30,372,041 — -7,750,188

Peers — same industry

TickerNameMarket CapLastDaily %
LLY ELI LILLY & Co $1.01T $1133.00 —
JNJ JOHNSON & JOHNSON $579.83B $240.87 —
ABBV AbbVie Inc. $402.35B $227.73 —
MRK Merck & Co., Inc. $294.03B $119.05 —
NVS NOVARTIS AG $292.07B $153.07 —

News headlines (Yahoo Finance, 1h cache)

BriaCell Therapeutics Announces Closing of Offering
2026-06-02 20:05 · Yahoo
BriaCell Presenting Final Phase 2, Ongoing Phase 3 Data at ASCO Meeting
2026-06-01 13:57 · Yahoo
BriaCell Presents Positive Clinical Data at ASCO 2026
2026-06-01 11:30 · Yahoo
BriaCell Therapeutics Announces Pricing of Offering
2026-05-31 23:59 · Yahoo
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
2026-05-26 11:30 · Yahoo
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
2026-05-22 11:30 · Yahoo
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
2026-05-15 11:30 · Yahoo
BriaCell Therapeutics Completes Manufacturing Bria-PROS+ Clinical Supplies
2026-05-14 12:45 · Yahoo
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
2026-05-14 11:30 · Yahoo
BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
2026-05-13 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.
SEC EDGAR filings → · StockAnalysis.com → · OpenInsider →